sorafenib ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors 2459 284461-73-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY 43-9006
  • BAY 545-9085
  • BAY-545-9085
  • sorafenib tosilate
  • sorafenib
  • nexavar
  • sorafenib tosylate
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
  • Molecular weight: 464.83
  • Formula: C21H16ClF3N4O3
  • CLOGP: 5.16
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 3
  • TPSA: 92.35
  • ALOGS: -5.43
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 12.29 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 39 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2005 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1562.83 20.15 458 13927 19640 50571099
Hepatic cancer 216.32 20.15 66 14319 3209 50587530
Hepatic function abnormal 214.91 20.15 127 14258 32554 50558185
Diarrhoea 203.22 20.15 486 13899 587990 50002749
Hepatic encephalopathy 176.16 20.15 75 14310 9561 50581178
Decreased appetite 164.28 20.15 241 14144 200682 50390057
Rash 142.55 20.15 354 14031 437117 50153622
Off label use 140.24 20.15 370 14015 474056 50116683
Hypertension 130.59 20.15 223 14162 210980 50379759
Blister 123.04 20.15 136 14249 85282 50505457
Metastases to lung 114.52 20.15 58 14327 10962 50579777
Hyperkeratosis 111.66 20.15 45 14340 4990 50585749
Skin exfoliation 104.01 20.15 82 14303 33530 50557209
Ascites 99.34 20.15 82 14303 35779 50554960
Drug ineffective 93.96 20.15 59 14326 819274 49771465
Amylase increased 85.32 20.15 38 14347 5392 50585347
Dry skin 82.38 20.15 80 14305 43111 50547628
Hepatocellular carcinoma 77.84 20.15 27 14358 1972 50588767
Pain of skin 77.27 20.15 40 14345 7907 50582832
Alopecia 74.91 20.15 194 14191 244853 50345886
Stomatitis 71.87 20.15 114 14271 101230 50489509
Alpha 1 foetoprotein increased 71.04 20.15 15 14370 156 50590583
Product use in unapproved indication 69.69 20.15 121 14264 115698 50475041
Lipase increased 66.25 20.15 37 14348 8504 50582235
Hepatic failure 60.05 20.15 59 14326 32224 50558515
Erythema multiforme 58.98 20.15 35 14350 9015 50581724
Erythema 54.33 20.15 125 14260 146289 50444450
Palmoplantar keratoderma 53.23 20.15 11 14374 102 50590637
Drug hypersensitivity 50.65 20.15 6 14379 251004 50339735
Skin toxicity 47.80 20.15 23 14362 3890 50586849
Ammonia increased 46.04 20.15 23 14362 4218 50586521
Rheumatoid arthritis 45.82 20.15 3 14382 202547 50388192
Blood bilirubin increased 44.31 20.15 50 14335 31988 50558751
Platelet count decreased 40.69 20.15 89 14296 100637 50490102
Food refusal 37.03 20.15 10 14375 312 50590427
Hypophosphataemia 36.08 20.15 25 14360 8389 50582350
Protein induced by vitamin K absence or antagonist II increased 35.83 20.15 5 14380 0 50590739
Blood pressure increased 35.15 20.15 100 14285 133032 50457707
Catabolic state 34.69 20.15 7 14378 57 50590682
Pain in extremity 34.39 20.15 161 14224 272704 50318035
Condition aggravated 34.36 20.15 21 14364 297037 50293702
Arthropathy 33.83 20.15 3 14382 157903 50432836
Liver disorder 33.71 20.15 47 14338 37175 50553564
Abdominal pain 33.21 20.15 144 14241 236084 50354655
Weight decreased 32.75 20.15 137 14248 221108 50369631
Liver carcinoma ruptured 31.89 20.15 5 14380 6 50590733
Death 30.62 20.15 177 14208 325202 50265537
Pancreatic enzymes increased 29.83 20.15 10 14375 658 50590081
Hospitalisation 29.69 20.15 62 14323 67875 50522864
Oral pain 29.51 20.15 36 14349 24997 50565742
Tumour necrosis 28.91 20.15 10 14375 724 50590015
Renal cell carcinoma 28.33 20.15 15 14370 3102 50587637
Weight increased 28.29 20.15 11 14374 201880 50388859
Sinusitis 28.00 20.15 7 14378 170551 50420188
Hyperammonaemia 27.51 20.15 17 14368 4707 50586032
Mucosal inflammation 26.83 20.15 44 14341 40098 50550641
Swelling 26.45 20.15 12 14373 200860 50389879
Joint swelling 26.11 20.15 19 14366 245267 50345472
Plantar erythema 26.00 20.15 7 14378 216 50590523
Pyrexia 24.38 20.15 188 14197 380015 50210724
Jaundice 23.37 20.15 33 14352 26396 50564343
Pain 22.97 20.15 86 14299 578817 50011922
Tumour haemorrhage 22.96 20.15 10 14375 1345 50589394
Acute myeloid leukaemia recurrent 22.71 20.15 10 14375 1380 50589359
Tumour thrombosis 22.65 20.15 4 14381 14 50590725
Gait inability 22.64 20.15 39 14346 36988 50553751
Asthenia 22.27 20.15 161 14224 318881 50271858
Soft tissue necrosis 21.90 20.15 7 14378 396 50590343
Malignant neoplasm progression 21.82 20.15 55 14330 68069 50522670
Nasopharyngitis 21.78 20.15 14 14371 192913 50397826
Hypocalcaemia 21.55 20.15 32 14353 26784 50563955
Metastases to bone 21.40 20.15 26 14359 17969 50572770
Dysphonia 21.25 20.15 39 14346 38853 50551886
Metastatic renal cell carcinoma 20.91 20.15 8 14377 772 50589967
Hepatic rupture 20.61 20.15 4 14381 26 50590713
Tumour rupture 20.32 20.15 5 14380 107 50590632

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 3725.42 16.55 1153 33502 13606 29526266
Hepatic cancer 846.21 16.55 309 34346 6147 29533725
Hepatic function abnormal 652.28 16.55 462 34193 38797 29501075
Hepatic encephalopathy 585.95 16.55 292 34363 12743 29527129
Diarrhoea 583.51 16.55 1230 33425 331468 29208404
Ascites 493.37 16.55 380 34275 36239 29503633
Decreased appetite 451.02 16.55 691 33964 144651 29395221
Hypertension 409.70 16.55 588 34067 116026 29423846
Metastases to lung 335.32 16.55 170 34485 7685 29532187
Hepatic failure 333.19 16.55 284 34371 31228 29508644
Alopecia 331.39 16.55 231 34424 18853 29521019
Blister 268.73 16.55 207 34448 19699 29520173
Dysphonia 253.42 16.55 197 34458 18999 29520873
Alpha 1 foetoprotein increased 235.75 16.55 67 34588 564 29539308
Rash 202.12 16.55 582 34073 189237 29350635
Amylase increased 165.34 16.55 93 34562 5187 29534685
Liver carcinoma ruptured 141.98 16.55 34 34621 131 29539741
Ammonia increased 134.41 16.55 74 34581 3957 29535915
Blood bilirubin increased 129 16.55 178 34477 33715 29506157
Drug ineffective 125.59 16.55 145 34510 363025 29176847
Jaundice 113.19 16.55 155 34500 29141 29510731
Hyperkeratosis 111.72 16.55 61 34594 3208 29536664
Skin exfoliation 109.70 16.55 134 34521 22511 29517361
Stomatitis 106.85 16.55 171 34484 36942 29502930
Liver disorder 105.98 16.55 146 34509 27603 29512269
Toxicity to various agents 105.54 16.55 36 34619 173625 29366247
Oesophageal varices haemorrhage 102.37 16.55 54 34601 2648 29537224
Lipase increased 102.30 16.55 82 34573 8255 29531617
Fatigue 96.34 16.55 667 33988 316154 29223718
Hepatocellular carcinoma 94.49 16.55 73 34582 6965 29532907
Metastases to bone 88.10 16.55 81 34574 9817 29530055
Drug interaction 88.08 16.55 62 34593 197323 29342549
Acute kidney injury 87.16 16.55 110 34545 265157 29274715
Completed suicide 85.64 16.55 5 34650 90241 29449631
Dry skin 85.06 16.55 120 34535 23187 29516685
Hypophosphataemia 80.74 16.55 70 34585 7854 29532018
Metastases to lymph nodes 77.65 16.55 52 34603 3965 29535907
Tumour rupture 76.69 16.55 22 34633 192 29539680
Portal vein thrombosis 74.17 16.55 47 34608 3262 29536610
Overdose 74 16.55 5 34650 79814 29460058
Renal cell carcinoma 72.58 16.55 53 34602 4643 29535229
Abdominal pain 69.34 16.55 328 34327 135029 29404843
Abdominal pain upper 66.47 16.55 189 34466 60804 29479068
Pain of skin 65.73 16.55 46 34609 3769 29536103
Platelet count decreased 65.22 16.55 269 34386 104403 29435469
Blood pressure increased 64.80 16.55 212 34443 73591 29466281
Tumour thrombosis 59.29 16.55 14 34641 50 29539822
Erythema multiforme 58.87 16.55 58 34597 7659 29532213
Weight decreased 58.84 16.55 339 34316 150566 29389306
Aspartate aminotransferase increased 58.32 16.55 178 34477 59547 29480325
Hepatorenal syndrome 57.36 16.55 35 34620 2271 29537601
Asthenia 54.25 16.55 434 34221 214816 29325056
Pain in extremity 52.48 16.55 262 34393 110171 29429701
Metastases to adrenals 51.68 16.55 24 34631 891 29538981
Fall 49.67 16.55 82 34573 177096 29362776
Protein induced by vitamin K absence or antagonist II increased 49.19 16.55 10 34645 13 29539859
Pancreatic enzymes increased 48.19 16.55 20 34635 564 29539308
Metastatic renal cell carcinoma 47.65 16.55 29 34626 1873 29537999
Drug hypersensitivity 47.38 16.55 11 34644 68395 29471477
Hypotension 47.35 16.55 98 34557 194256 29345616
Pneumonia 47.31 16.55 204 34451 319968 29219904
Metastases to spine 46.52 16.55 30 34625 2146 29537726
Skin toxicity 46.06 16.55 37 34618 3734 29536138
Metastases to central nervous system 46.05 16.55 49 34606 7082 29532790
Gait inability 45.27 16.55 79 34576 18296 29521576
Off label use 45.09 16.55 544 34111 300256 29239616
Skin fissures 44.81 16.55 37 34618 3882 29535990
Coma hepatic 42.87 16.55 17 34638 425 29539447
Neutropenia 42.73 16.55 55 34600 131656 29408216
Metastases to peritoneum 40.21 16.55 24 34631 1496 29538376
Hepatic rupture 39.82 16.55 9 34646 25 29539847
Tumour marker increased 39.46 16.55 17 34638 527 29539345
Liver abscess 39.18 16.55 32 34623 3306 29536566
Cerebral infarction 37.80 16.55 87 34568 24588 29515284
Condition aggravated 35.40 16.55 74 34581 146221 29393651
Nephrotic syndrome 34.85 16.55 40 34615 6288 29533584
Weight increased 34.22 16.55 24 34631 76643 29463229
Cardiac arrest 34.16 16.55 30 34625 85561 29454311
Tumour haemorrhage 33.84 16.55 26 34629 2459 29537413
Hospitalisation 33.30 16.55 124 34531 45864 29494008
Gastric ulcer 32.76 16.55 59 34596 14002 29525870
Product administered to patient of inappropriate age 32.32 16.55 26 34629 2629 29537243
COVID-19 31.29 16.55 3 34652 36011 29503861
Coronary artery disease 30.80 16.55 7 34648 44183 29495689
Reactive perforating collagenosis 30.35 16.55 6 34649 6 29539866
Varicose vein ruptured 30.09 16.55 7 34648 23 29539849
Malignant neoplasm progression 30.07 16.55 168 34487 73691 29466181
Pyrexia 29.99 16.55 488 34167 287134 29252738
General physical health deterioration 29.51 16.55 214 34441 102643 29437229
Bradycardia 28.69 16.55 21 34634 65608 29474264
Cancer pain 28.60 16.55 23 34632 2324 29537548
Malaise 28.50 16.55 299 34356 159303 29380569
Death 28.46 16.55 560 34095 341524 29198348
Depression 28.17 16.55 35 34620 85112 29454760
Therapeutic product effect incomplete 27.85 16.55 6 34649 39299 29500573
Inappropriate schedule of product administration 27.33 16.55 9 34646 44463 29495409
Anxiety 27.30 16.55 36 34619 85329 29454543
Agitation 27.24 16.55 13 34642 51291 29488581
Hyperamylasaemia 27.21 16.55 13 34642 515 29539357
Haemobilia 26.95 16.55 11 34644 297 29539575
Erythema 26.92 16.55 166 34489 75440 29464432
Hyperammonaemia 26.58 16.55 33 34622 5630 29534242
Metastasis 26.58 16.55 26 34629 3403 29536469
Keratoacanthoma 26.33 16.55 13 34642 554 29539318
Febrile neutropenia 26.11 16.55 58 34597 112182 29427690
Plantar erythema 26.01 16.55 7 34648 47 29539825
Abdominal distension 25.46 16.55 114 34541 45797 29494075
Genital rash 25.46 16.55 12 34643 461 29539411
Epistaxis 25.46 16.55 124 34531 51580 29488292
Suicidal ideation 25.22 16.55 5 34650 34711 29505161
Intentional product misuse 25.16 16.55 5 34650 34656 29505216
Acute myeloid leukaemia recurrent 25.07 16.55 19 34636 1761 29538111
Lactic acidosis 25.05 16.55 3 34652 30244 29509628
Influenza 24.83 16.55 9 34646 41872 29498000
Alanine aminotransferase increased 24.77 16.55 155 34500 70789 29469083
Varices oesophageal 24.65 16.55 24 34631 3122 29536750
Hepatic lesion 24.63 16.55 24 34631 3126 29536746
Haematemesis 24.57 16.55 74 34581 24552 29515320
Therapeutic product effect decreased 24.20 16.55 3 34652 29448 29510424
Glossodynia 24.04 16.55 24 34631 3219 29536653
Incorrect dose administered 23.44 16.55 5 34650 32979 29506893
Proteinuria 23.41 16.55 55 34600 15749 29524123
Gastric antral vascular ectasia 23.36 16.55 10 34645 305 29539567
Oxygen saturation decreased 22.93 16.55 12 34643 44925 29494947
Sinusitis 22.85 16.55 6 34649 34344 29505528
Electrocardiogram QT prolonged 22.76 16.55 7 34648 36130 29503742
Tachycardia 22.68 16.55 31 34624 72379 29467493
Nasopharyngitis 22.51 16.55 22 34633 59643 29480229
Intentional product use issue 22.21 16.55 11 34644 42487 29497385
Hypersensitivity 21.76 16.55 18 34637 52885 29486987
Gingival bleeding 21.74 16.55 32 34623 6421 29533451
Rhabdomyolysis 21.17 16.55 24 34631 60784 29479088
Melaena 20.86 16.55 82 34573 31094 29508778
Chronic obstructive pulmonary disease 20.81 16.55 11 34644 40944 29498928
Hepatic infarction 20.25 16.55 8 34647 198 29539674
Skin ulcer 20.12 16.55 58 34597 18782 29521090
Cardiac failure congestive 20.00 16.55 37 34618 76544 29463328
Wheezing 19.95 16.55 7 34648 33233 29506639
Hyperhidrosis 19.84 16.55 28 34627 64512 29475360
Syncope 19.79 16.55 41 34614 81330 29458542
Neuropathy peripheral 19.74 16.55 33 34622 70994 29468878
Chronic kidney disease 19.68 16.55 9 34646 36407 29503465
Palmoplantar keratoderma 19.59 16.55 9 34646 326 29539546
Faeces discoloured 19.27 16.55 46 34609 13305 29526567
Pruritus 19.02 16.55 215 34440 116634 29423238
Hepatic artery thrombosis 19.00 16.55 8 34647 234 29539638
Hepatic cirrhosis 18.97 16.55 48 34607 14396 29525476
Asthma 18.87 16.55 8 34647 33841 29506031
Lower respiratory tract infection 18.87 16.55 4 34651 26498 29513374
Hypoalbuminaemia 18.81 16.55 39 34616 10266 29529606
Cardio-respiratory arrest 18.69 16.55 19 34636 50582 29489290
Hepatic cancer metastatic 18.69 16.55 11 34644 668 29539204
Glossitis 18.68 16.55 13 34642 1055 29538817
Urticaria 18.57 16.55 22 34633 54638 29485234
Thyroid cancer metastatic 18.52 16.55 5 34650 34 29539838
Nausea 18.42 16.55 456 34199 288799 29251073
Product dose omission issue 18.42 16.55 55 34600 96328 29443544
Drug reaction with eosinophilia and systemic symptoms 18.41 16.55 5 34650 27987 29511885
Aortic dissection 18.33 16.55 18 34637 2366 29537506
Food refusal 18.28 16.55 7 34648 159 29539713
Wrong technique in product usage process 18.22 16.55 7 34648 31421 29508451
Feeding disorder 18.20 16.55 28 34627 5839 29534033
Joint swelling 17.92 16.55 19 34636 49611 29490261
Prostate cancer 17.87 16.55 4 34651 25523 29514349
Oropharyngeal blistering 17.69 16.55 7 34648 174 29539698
Tumour embolism 17.39 16.55 5 34650 44 29539828
Thyroid atrophy 17.25 16.55 3 34652 0 29539872
Metastases to gallbladder 17.25 16.55 3 34652 0 29539872
Encephalopathy 17.14 16.55 77 34578 30966 29508906

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 4977.42 16.09 1491 43403 27328 64426510
Hepatic cancer 1038.70 16.09 328 44566 7120 64446718
Hepatic function abnormal 867.23 16.09 546 44348 63767 64390071
Hepatic encephalopathy 747.83 16.09 341 44553 20725 64433113
Diarrhoea 709.77 16.09 1550 43344 721154 63732684
Decreased appetite 613.46 16.09 860 44034 280429 64173409
Ascites 571.31 16.09 416 44478 61585 64392253
Hypertension 495.37 16.09 745 44149 258516 64195322
Metastases to lung 439.69 16.09 214 44680 15050 64438788
Hepatic failure 383.95 16.09 314 44580 55080 64398758
Alpha 1 foetoprotein increased 304.14 16.09 76 44818 664 64453174
Rash 276.69 16.09 821 44073 457728 63996110
Blister 246.99 16.09 293 44601 80674 64373164
Amylase increased 238.18 16.09 122 44772 9563 64444275
Dysphonia 219.63 16.09 212 44682 46170 64407668
Hyperkeratosis 202.41 16.09 97 44797 6584 64447254
Skin exfoliation 201.01 16.09 199 44695 44686 64409152
Drug ineffective 199.38 16.09 176 44718 840071 63613767
Alopecia 191.62 16.09 382 44512 165308 64288530
Hepatocellular carcinoma 184.18 16.09 98 44796 8305 64445533
Lipase increased 175.74 16.09 115 44779 14287 64439551
Ammonia increased 168.98 16.09 87 44807 6890 64446948
Blood bilirubin increased 166.79 16.09 203 44691 57350 64396488
Liver carcinoma ruptured 163.86 16.09 35 44859 137 64453701
Dry skin 154.04 16.09 184 44710 50977 64402861
Jaundice 151.89 16.09 178 44716 48334 64405504
Completed suicide 134.25 16.09 5 44889 224409 64229429
Stomatitis 134.24 16.09 259 44635 109346 64344492
Off label use 131.70 16.09 820 44074 631986 63821852
Platelet count decreased 130.18 16.09 330 44564 167381 64286457
Liver disorder 129.00 16.09 172 44722 53179 64400659
Oesophageal varices haemorrhage 120.09 16.09 56 44838 3573 64450265
Pain of skin 118.34 16.09 77 44817 9470 64444368
Drug hypersensitivity 117.21 16.09 14 44880 237801 64216037
Hypophosphataemia 109.41 16.09 87 44807 14633 64439205
Renal cell carcinoma 108.48 16.09 62 44832 6042 64447796
Toxicity to various agents 105.66 16.09 61 44833 363452 64090386
Weight decreased 97.95 16.09 426 44468 285313 64168525
Rheumatoid arthritis 97.08 16.09 4 44890 164290 64289548
Erythema multiforme 96.27 16.09 83 44811 15618 64438220
Death 94.89 16.09 617 44277 482088 63971750
Portal vein thrombosis 92.21 16.09 52 44842 4939 64448899
Overdose 90.69 16.09 5 44889 159561 64294277
Metastases to bone 90.33 16.09 90 44804 20345 64433493
Skin toxicity 88.64 16.09 56 44838 6546 64447292
Asthenia 87.68 16.09 553 44341 427491 64026347
Fatigue 86.71 16.09 847 44047 747883 63705955
Tumour rupture 85.68 16.09 24 44870 337 64453501
Blood pressure increased 85.19 16.09 289 44605 172263 64281575
Abdominal pain 79.79 16.09 428 44466 311947 64141891
Protein induced by vitamin K absence or antagonist II increased 79.14 16.09 14 44880 12 64453826
Weight increased 79.13 16.09 25 44869 213323 64240515
Tumour thrombosis 75.40 16.09 17 44877 90 64453748
Condition aggravated 74.34 16.09 90 44804 372336 64081502
Hospitalisation 73.49 16.09 162 44732 75045 64378793
Fall 72.84 16.09 111 44783 416715 64037123
Drug interaction 72.80 16.09 87 44807 361996 64091842
Pancreatic enzymes increased 71.16 16.09 28 44866 1173 64452665
Metastases to lymph nodes 70.14 16.09 54 44840 8663 64445175
Aspartate aminotransferase increased 68.47 16.09 211 44683 119577 64334261
Joint swelling 67.12 16.09 33 44861 215349 64238489
Sinusitis 66.21 16.09 11 44883 145917 64307921
Malignant neoplasm progression 64.68 16.09 199 44695 112672 64341166
Palmoplantar keratoderma 64.53 16.09 20 44874 406 64453432
Therapeutic product effect decreased 64.36 16.09 4 44890 115347 64338491
Hypotension 63.19 16.09 105 44789 380869 64072969
Nasopharyngitis 62.69 16.09 29 44865 196044 64257794
Gait inability 61.75 16.09 108 44786 42260 64411578
Pyrexia 61.56 16.09 626 44268 558018 63895820
Metastases to adrenals 61.04 16.09 25 44869 1164 64452674
Acute kidney injury 59.72 16.09 141 44753 449099 64004739
Metastases to spine 59.42 16.09 35 44859 3608 64450230
Hypersensitivity 58.39 16.09 32 44862 196420 64257418
Pain in extremity 57.30 16.09 384 44510 302701 64151137
Product use in unapproved indication 57.14 16.09 259 44635 176359 64277479
Liver abscess 56.81 16.09 39 44855 5241 64448597
Hepatorenal syndrome 55.93 16.09 34 44860 3712 64450126
Metastases to central nervous system 53.75 16.09 57 44837 13855 64439983
Tumour haemorrhage 52.92 16.09 32 44862 3461 64450377
Cerebral infarction 52.66 16.09 99 44795 40945 64412893
Coma hepatic 51.00 16.09 21 44873 991 64452847
Lower respiratory tract infection 50.69 16.09 4 44890 94610 64359228
Arthralgia 49.55 16.09 151 44743 442109 64011729
Acute myeloid leukaemia recurrent 48.72 16.09 28 44866 2756 64451082
Hyperammonaemia 48.22 16.09 46 44848 9858 64443980
Product administered to patient of inappropriate age 47.19 16.09 33 44861 4568 64449270
Food refusal 47.08 16.09 16 44878 439 64453399
Skin fissures 44.82 16.09 45 44849 10261 64443577
Hepatic rupture 44.66 16.09 10 44884 51 64453787
Therapeutic product effect incomplete 44.35 16.09 9 44885 103473 64350365
Nephrotic syndrome 43.88 16.09 43 44851 9524 64444314
Erythema 43.45 16.09 250 44644 186820 64267018
Cancer pain 42.42 16.09 30 44864 4227 64449611
Inappropriate schedule of product administration 41.76 16.09 7 44887 92279 64361559
Plantar erythema 41.13 16.09 13 44881 282 64453556
Metastatic renal cell carcinoma 40.89 16.09 23 44871 2173 64451665
Anxiety 40.34 16.09 49 44845 202600 64251238
Metastases to peritoneum 40.06 16.09 27 44867 3520 64450318
Abdominal pain upper 40.05 16.09 233 44661 174797 64279041
General physical health deterioration 38.57 16.09 259 44635 204166 64249672
Treatment failure 37.75 16.09 17 44877 116799 64337039
Tumour necrosis 37.64 16.09 20 44874 1689 64452149
Asthma 37.40 16.09 10 44884 95215 64358623
Pleural effusion 36.81 16.09 180 44714 126379 64327459
Bone marrow failure 36.75 16.09 94 44800 47858 64405980
Metastasis 36.73 16.09 31 44863 5664 64448174
Bronchitis 36.45 16.09 15 44879 108728 64345110
Oxygen saturation decreased 35.58 16.09 15 44879 107161 64346677
Pneumonia 35.52 16.09 236 44658 559340 63894498
Cardiac arrest 35.41 16.09 33 44861 154031 64299807
COVID-19 34.21 16.09 3 44891 65137 64388701
Hepatic lesion 34.11 16.09 30 44864 5794 64448044
Reactive perforating collagenosis 33.47 16.09 6 44888 6 64453832
Varices oesophageal 33.24 16.09 28 44866 5102 64448736
Gastric ulcer 32.83 16.09 68 44826 30166 64423672
Swelling 32.67 16.09 38 44856 160180 64293658
Influenza 32.15 16.09 17 44877 106514 64347324
Proteinuria 32.05 16.09 64 44830 27659 64426179
Abdominal distension 31.93 16.09 142 44752 95852 64357986
Epistaxis 31.77 16.09 144 44750 97987 64355851
Alanine aminotransferase increased 31.74 16.09 185 44709 138846 64314992
Gastric antral vascular ectasia 31.57 16.09 14 44880 794 64453044
Gingival bleeding 31.54 16.09 45 44849 14809 64439029
Musculoskeletal stiffness 31.24 16.09 24 44870 123182 64330656
Depression 30.81 16.09 50 44844 183241 64270597
Pain 30.50 16.09 243 44651 553268 63900570
Oropharyngeal blistering 30.22 16.09 13 44881 685 64453153
Catabolic state 30.03 16.09 8 44886 92 64453746
Bradycardia 30.01 16.09 23 44871 118196 64335642
Upper respiratory tract infection 29.83 16.09 7 44887 72778 64381060
Melaena 29.34 16.09 93 44801 53455 64400383
Arthritis 29.01 16.09 11 44883 83803 64370035
Oral pain 28.87 16.09 61 44833 27432 64426406
Intentional product use issue 27.64 16.09 16 44878 95348 64358490
Intentional product misuse 27.63 16.09 8 44886 72287 64381551
Blood lactate dehydrogenase increased 27.61 16.09 67 44827 33011 64420827
Headache 27.55 16.09 236 44658 529231 63924607
Metastases to liver 27.36 16.09 55 44839 23886 64429952
Wheezing 27.19 16.09 11 44883 80568 64373270
Hyperamylasaemia 27.18 16.09 13 44881 878 64452960
Hypoalbuminaemia 26.98 16.09 46 44848 17628 64436210
Skin ulcer 26.54 16.09 79 44815 43895 64409943
Dehydration 26.23 16.09 248 44646 216515 64237323
Haemobilia 26.17 16.09 10 44884 387 64453451
Suicidal ideation 26.11 16.09 7 44887 66535 64387303
Urinary tract infection 25.93 16.09 79 44815 231517 64222321
Injury 25.88 16.09 4 44890 55988 64397850
Glossitis 25.87 16.09 20 44874 3227 64450611
Pericarditis 25.64 16.09 6 44888 62510 64391328
Dysphagia 25.60 16.09 144 44750 106668 64347170
Neutropenia 25.25 16.09 84 44810 239540 64214298
Haematemesis 25.18 16.09 81 44813 46918 64406920
Fluid intake reduced 25.03 16.09 24 44870 5176 64448662
Cholangitis 24.83 16.09 34 44860 10768 64443070
Tumour marker increased 24.80 16.09 20 44874 3430 64450408
Lymphadenopathy mediastinal 24.80 16.09 21 44873 3855 64449983
Aortic dissection 24.79 16.09 20 44874 3432 64450406
Hyperbilirubinaemia 24.57 16.09 49 44845 21156 64432682
Stress 24.45 16.09 6 44888 60528 64393310
Gastrointestinal perforation 24.17 16.09 24 44870 5400 64448438
Agitation 23.99 16.09 16 44878 88351 64365487
Nasal congestion 23.93 16.09 6 44888 59652 64394186
Keratoacanthoma 23.79 16.09 12 44882 910 64452928
Anaphylactic reaction 23.78 16.09 9 44885 68655 64385183
Wound 23.37 16.09 12 44882 76465 64377373
Urticaria 23.09 16.09 42 44852 147275 64306563
Thyroid cancer metastatic 23.02 16.09 7 44887 133 64453705
Renal cell carcinoma stage IV 23.02 16.09 6 44888 63 64453775
Feeding disorder 22.88 16.09 36 44858 12913 64440925
Discomfort 22.83 16.09 14 44880 80864 64372974
Incorrect dose administered 22.72 16.09 7 44887 60758 64393080
Osteoarthritis 22.45 16.09 8 44886 63328 64390510
Faeces discoloured 22.43 16.09 53 44841 25676 64428162
Hypocalcaemia 22.40 16.09 72 44822 41681 64412157
Medication error 22.14 16.09 4 44890 49962 64403876
Migraine 22.07 16.09 8 44886 62669 64391169
Varicose vein ruptured 21.78 16.09 6 44888 79 64453759
Hiccups 21.77 16.09 28 44866 8348 64445490
Somnolence 21.72 16.09 71 44823 203574 64250264
Tachycardia 21.41 16.09 45 44849 149534 64304304
Blood albumin decreased 21.26 16.09 46 44848 21027 64432811
Hyperhidrosis 21.06 16.09 34 44860 124886 64328952
Eating disorder 20.89 16.09 40 44854 16765 64437073
Cataract 20.87 16.09 5 44889 51257 64402581
Coronary artery disease 20.80 16.09 8 44886 60425 64393413
Metastases to abdominal cavity 20.61 16.09 9 44885 492 64453346
Chronic obstructive pulmonary disease 20.48 16.09 12 44882 71036 64382802
Wrong technique in product usage process 20.15 16.09 10 44884 64964 64388874
Tumour pain 20.14 16.09 14 44880 1919 64451919
Hepatic cancer metastatic 19.89 16.09 10 44884 753 64453085
Aggression 19.85 16.09 4 44890 46228 64407610
Metastases to heart 19.61 16.09 7 44887 223 64453615
Electrocardiogram QT prolonged 19.47 16.09 16 44878 79432 64374406
Osteoporosis 19.46 16.09 3 44891 42077 64411761
Cardio-respiratory arrest 19.34 16.09 24 44870 98369 64355469
Dizziness 19.23 16.09 199 44695 429964 64023874
Gastrointestinal toxicity 19.14 16.09 21 44873 5301 64448537
Haemoptysis 18.98 16.09 76 44818 48972 64404866
Rhinorrhoea 18.95 16.09 9 44885 59960 64393878
Alpha 1 foetoprotein abnormal 18.89 16.09 5 44889 56 64453782
Genital rash 18.66 16.09 10 44884 859 64452979
Hepatic pain 18.43 16.09 17 44877 3491 64450347
Mucosal inflammation 18.17 16.09 89 44805 62495 64391343
Adverse drug reaction 18.04 16.09 71 44823 45393 64408445
Chronic kidney disease 17.83 16.09 9 44885 57910 64395928
Blood sodium decreased 17.82 16.09 53 44841 29429 64424409
Therapy non-responder 17.79 16.09 12 44882 65887 64387951
Scrotal ulcer 17.59 16.09 7 44887 302 64453536
Syncope 17.47 16.09 54 44840 157581 64296257
Tongue blistering 17.44 16.09 11 44883 1282 64452556
Metastases to spleen 17.34 16.09 8 44886 498 64453340
C-reactive protein increased 17.13 16.09 119 44775 94790 64359048
Product dose omission issue 16.80 16.09 74 44820 194673 64259165
Encephalopathy 16.62 16.09 83 44811 58736 64395102
Gastrointestinal disorder 16.49 16.09 23 44871 89686 64364152
Cognitive disorder 16.31 16.09 9 44885 55078 64398760
Hot flush 16.11 16.09 6 44888 46229 64407609

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50925 serine/threonine protein kinase inhibitor
CHEBI has role CHEBI:149553 anticoronaviral drug
CHEBI has role CHEBI:173085 ferroptosis inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Carcinoma of thyroid indication 448216007
Renal cell carcinoma indication 702391001 DOID:4450
Hypophosphatemia contraindication 4996001
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Pancreatitis contraindication 75694006 DOID:4989
Angina pectoris contraindication 194828000
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.84 acidic
pKa2 11.97 acidic
pKa3 12.61 acidic
pKa4 2.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8618141 Feb. 11, 2023 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8877933 Dec. 24, 2027 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase INHIBITOR Ki 8.22 CHEMBL CHEMBL
Serine/threonine-protein kinase B-raf Kinase INHIBITOR Ki 7.66 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 8.35 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Kd 8.13 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.51 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 10.68 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.43 CHEMBL CHEMBL
Epidermal growth factor receptor Kinase IC50 8.53 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.09 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.41 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 5.57 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.08 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.70 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.55 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.21 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.06 CHEMBL
Insulin receptor Kinase AGONIST IC50 5.28 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.38 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.07 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.44 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.54 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.68 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.02 CHEMBL
Hepatocyte growth factor receptor Kinase IC50 5.24 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 5.52 CHEMBL
LIM domain kinase 1 Kinase Kd 5.80 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.60 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.21 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.47 CHEMBL
Aurora kinase C Kinase Kd 6.68 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.46 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.70 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6.44 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 5.89 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase 3 Kinase IC50 7.74 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.62 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.10 CHEMBL
Mitogen-activated protein kinase 12 Kinase Kd 5.12 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.11 CHEMBL
Aurora kinase A Kinase IC50 5.42 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.42 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.59 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.36 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.12 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.80 CHEMBL
Glycogen synthase kinase-3 beta Kinase IC50 5.08 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.77 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.17 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.44 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.82 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.74 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.54 CHEMBL
Bifunctional epoxide hydrolase 2 Enzyme IC50 7.92 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.16 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 6.96 CHEMBL
Cyclin-dependent kinase 6 Kinase IC50 6.89 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 5.35 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 5.72 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.85 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.12 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase 13 Kinase Kd 5.18 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.80 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.54 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 8.20 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 7.17 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
LIM domain kinase 2 Kinase Kd 5.02 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 6.64 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.55 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.18 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 5.32 CHEMBL
Aurora kinase B Kinase Kd 6.36 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.32 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.44 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 6.60 CHEMBL
Cyclin-dependent kinase 8 Kinase Kd 6.51 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.89 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.21 CHEMBL
Myosin-IIIb Kinase Kd 5.15 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 5.42 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.01 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase 15 Kinase Kd 7.34 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase IC50 5.82 CHEMBL
Casein kinase I isoform alpha Kinase IC50 6.60 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 6.89 CHEMBL
Cyclin-dependent kinase-like 3 Kinase Kd 6.31 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.62 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.77 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.41 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 8.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.16 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.27 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.96 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.42 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.27 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Myosin light chain kinase 3 Kinase Kd 5.02 CHEMBL
Serine/threonine-protein kinase A-Raf Kinase IC50 8.15 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase IC50 4.84 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.14 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.93 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.71 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7.25 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.38 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 5.21 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.15 CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 5.48 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.89 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 6.65 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.66 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 7.82 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.59 CHEMBL
Purine nucleoside phosphorylase Enzyme IC50 7.90 CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 7.70 IUPHAR
Platelet-derived growth factor receptor beta Kinase INHIBITOR IC50 7.24 IUPHAR
Serine/threonine-protein kinase B-raf Kinase IC50 6.89 CHEMBL

External reference:

IDSource
4025077 VUID
N0000175349 NUI
D06272 KEGG_DRUG
475207-59-1 SECONDARY_CAS_RN
4025077 VANDF
C1516119 UMLSCUI
CHEBI:50924 CHEBI
BAX PDB_CHEM_ID
CHEMBL1336 ChEMBL_ID
CHEMBL1200485 ChEMBL_ID
D000077157 MESH_DESCRIPTOR_UI
DB00398 DRUGBANK_ID
5711 IUPHAR_LIGAND_ID
8234 INN_ID
9ZOQ3TZI87 UNII
216239 PUBCHEM_CID
495881 RXNORM
20792 MMSL
73580 MMSL
d05691 MMSL
011160 NDDF
011161 NDDF
420681006 SNOMEDCT_US
422042001 SNOMEDCT_US
432886002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sorafenib Tosylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-1201 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 43598-458 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
Nexavar HUMAN PRESCRIPTION DRUG LABEL 1 50419-488 TABLET, FILM COATED 200 mg ORAL NDA 28 sections